Core Insights - The collaboration between Paige Biopharma and PDC grants exclusive rights for the development, distribution, marketing, and commercialization of Visepegenatide (PB-119) in the Middle East and Africa [1] Market Opportunity - The Middle East and North Africa (MENA) region has a high diabetes prevalence rate of 16.2%, the highest globally, driven by dietary and lifestyle factors [2] - The pharmaceutical market for digestive and metabolic drugs, including diabetes treatments, holds a 20.4% market share in the region, with a significant growth of 22.1% in Q1 2025 [2] - The number of diabetes patients in Africa is projected to increase by nearly 142% by 2050, indicating substantial market potential for diabetes and obesity treatment drugs [2] - The global weight management drug market is expected to grow from $99.7 billion in 2020 to $112.8 billion by 2024, with a compound annual growth rate (CAGR) of 3.1%, potentially reaching $277.4 billion by 2034 [2] - The demand for weight management drugs in the MENA region is anticipated to be the highest globally, potentially reaching a scale of $10 billion by 2034 [2] Product Overview - Visepegenatide (PB-119) is a once-weekly subcutaneous GLP-1 receptor agonist developed by Paige Biopharma for the treatment of type 2 diabetes and weight management [3] - The product demonstrates superior clinical characteristics compared to some existing products, including good safety, tolerability, and significant effects on blood sugar reduction and weight loss [3] - The innovative molecular design and long-acting mechanism of Visepegenatide (PB-119) provide patients with a more convenient and stable treatment option, representing the future direction of GLP-1 therapies [3] - The partnership with PDC is expected to leverage local advantages to expedite the development, registration, and commercialization of Visepegenatide (PB-119) in the MENA region, creating long-term value for the company and hope for patients with metabolic diseases globally [3]